JP2013520166A - Ｒａｇｅ融合タンパク質及びその使用方法 - Google Patents

Ｒａｇｅ融合タンパク質及びその使用方法 Download PDF

Info

Publication number
JP2013520166A
JP2013520166A JP2012553874A JP2012553874A JP2013520166A JP 2013520166 A JP2013520166 A JP 2013520166A JP 2012553874 A JP2012553874 A JP 2012553874A JP 2012553874 A JP2012553874 A JP 2012553874A JP 2013520166 A JP2013520166 A JP 2013520166A
Authority
JP
Japan
Prior art keywords
rage
fusion protein
seq
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012553874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013520166A5 (enExample
Inventor
ロスレイン ロバート
シー．ウェブスター ジェフリー
ティー．ブレック グレゴリー
カトラガッダ マダン
ラジャドヒャクシャ マノイ
エヌ．バイオランド ベルナルド
ウエントランド ジョ−アン
Original Assignee
トランステック ファーマ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランステック ファーマ，インコーポレイティド filed Critical トランステック ファーマ，インコーポレイティド
Publication of JP2013520166A publication Critical patent/JP2013520166A/ja
Publication of JP2013520166A5 publication Critical patent/JP2013520166A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
JP2012553874A 2010-02-18 2010-10-19 Ｒａｇｅ融合タンパク質及びその使用方法 Pending JP2013520166A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30570610P 2010-02-18 2010-02-18
US61/305,706 2010-02-18
PCT/US2010/032270 WO2011102845A1 (en) 2010-02-18 2010-04-23 Rage fusion protein compositions and methods of use
USPCT/US2010/032270 2010-04-23
PCT/US2010/053157 WO2011102860A1 (en) 2010-02-18 2010-10-19 Rage fusion protein compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2013520166A true JP2013520166A (ja) 2013-06-06
JP2013520166A5 JP2013520166A5 (enExample) 2013-12-05

Family

ID=44483217

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012553874A Pending JP2013520166A (ja) 2010-02-18 2010-10-19 Ｒａｇｅ融合タンパク質及びその使用方法

Country Status (6)

Country Link
US (1) US20130142792A1 (enExample)
EP (1) EP2536750A1 (enExample)
JP (1) JP2013520166A (enExample)
CA (1) CA2789244A1 (enExample)
TW (1) TW201141507A (enExample)
WO (2) WO2011102845A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166885A1 (ja) * 2014-04-28 2015-11-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｈｇｆ凍結乾燥製剤
JP2022500086A (ja) * 2018-09-14 2022-01-04 バイオエイジ ラブス， インコーポレイテッド 改善された安定性およびリガンド結合親和性を有するｒａｇｅ融合タンパク質ならびにその使用
US11548926B2 (en) 2016-03-17 2023-01-10 Eisai R&D Management Co., Ltd. Method for producing an active hepatocyte growth factor (HGF)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628327A1 (en) 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR20140137347A (ko) * 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
MY186864A (en) * 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525171A (ja) * 2003-04-10 2007-09-06 ピーディーエル バイオファーマ，インコーポレイティド 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
JP2008512988A (ja) * 2004-08-03 2008-05-01 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
WO2008157378A2 (en) * 2007-06-14 2008-12-24 Galactica Pharmaceuticals Page fusion proteins
JP2009536201A (ja) * 2006-05-05 2009-10-08 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質、製剤及びその使用方法
JP2009232856A (ja) * 2001-05-24 2009-10-15 Zymogenetics Inc Ｔａｃｉ−免疫グロブリン融合タンパク質
JP2009261394A (ja) * 2000-12-12 2009-11-12 Medimmune Llc 延長した半減期を有する分子ならびにその組成物および用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
CN1805743A (zh) 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
DE102008037312B3 (de) 2008-08-11 2010-02-18 Emz-Hanauer Gmbh & Co. Kgaa Elektrischer Schalter, insbesondere in Mikroschalter-Bauform

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009261394A (ja) * 2000-12-12 2009-11-12 Medimmune Llc 延長した半減期を有する分子ならびにその組成物および用途
JP2009232856A (ja) * 2001-05-24 2009-10-15 Zymogenetics Inc Ｔａｃｉ−免疫グロブリン融合タンパク質
JP2007525171A (ja) * 2003-04-10 2007-09-06 ピーディーエル バイオファーマ，インコーポレイティド 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
JP2008512988A (ja) * 2004-08-03 2008-05-01 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
JP2009536201A (ja) * 2006-05-05 2009-10-08 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質、製剤及びその使用方法
WO2008157378A2 (en) * 2007-06-14 2008-12-24 Galactica Pharmaceuticals Page fusion proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN5013003310; ＳＲＩＫＲＩＳＨＮＡ: 'ＣＡＲＢＯＸＹＬＡＴＥＤ　Ｎ-ＧＬＹＣＡＮＳ　ＯＮ　ＲＡＧＥ　ＡＲＥ　ＣＲＩＴＩＣＡＬ　ＤＥＴＥＲＭＩＮＡＮＴＳ　ＯＦ　Ｓ１００Ａ１２　ＢＩＮＤＩＮＧ' ＡＢＳＴＲＡＣＴＳ　ＳＵＢＭＩＴＴＥＤ　ＦＯＲ　ＴＨＥ　２００５　ＭＥＥＴＩＮＧ　ＯＦ　ＴＨＥ　ＳＯＣＩＥＴＹ　ＦＯＲ　ＧＬＹＣＯＢＩＯＬＯＧＹ　［ＯＮＬＩＮＥ］ , 200511 *
JPN6014054972; Ｂｉｏｃｈｅｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　Ａｃｔａ　（２００７）　Ｖｏｌ．１７７０，　Ｎｏ．１０，　ｐｐ．１４６８-１４７４ *
JPN6014054975; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．　（１９９２）　Ｖｏｌ．２６７，　Ｎｏ．２３，　ｐｐ．１６３９６-１６４０２ *
JPN6014054976; Ｊｏｕｒｎａｌ　ｏｆ　Ｃｅｌｌｕｌａｒ　Ｂｉｏｃｈｅｍｉｓｔｒｙ　（２０１０）　Ｖｏｌ．１１０，　Ｎｏ．３，　ｐｐ．６４５-６５９ *
JPN6014054978; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．　（２００８）　Ｖｏｌ．２８３，　Ｎｏ．４０，　ｐｐ．２７２５５-２７２６９ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166885A1 (ja) * 2014-04-28 2015-11-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｈｇｆ凍結乾燥製剤
CN106456695A (zh) * 2014-04-28 2017-02-22 卫材R&D管理有限公司 Hgf的冻干配制品
JPWO2015166885A1 (ja) * 2014-04-28 2017-04-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｈｇｆ凍結乾燥製剤
AU2015254307B2 (en) * 2014-04-28 2019-11-07 Eisai R&D Management Co., Ltd. Lyophilized formulation of HGF
CN106456695B (zh) * 2014-04-28 2019-11-12 卫材R&D管理有限公司 Hgf的冻干配制品
US11547743B2 (en) 2014-04-28 2023-01-10 Eisai R&D Management Co., Ltd. Lyophilized formulation of HGF
US11548926B2 (en) 2016-03-17 2023-01-10 Eisai R&D Management Co., Ltd. Method for producing an active hepatocyte growth factor (HGF)
US12384824B2 (en) 2016-03-17 2025-08-12 Eisai R&D Management Co., Ltd. Method for producing an active hepatocyte growth factor (HGF)
JP2022500086A (ja) * 2018-09-14 2022-01-04 バイオエイジ ラブス， インコーポレイテッド 改善された安定性およびリガンド結合親和性を有するｒａｇｅ融合タンパク質ならびにその使用
JP7307178B2 (ja) 2018-09-14 2023-07-11 バイオエイジ ラブス， インコーポレイテッド 改善された安定性およびリガンド結合親和性を有するｒａｇｅ融合タンパク質ならびにその使用

Also Published As

Publication number Publication date
TW201141507A (en) 2011-12-01
EP2536750A1 (en) 2012-12-26
WO2011102860A1 (en) 2011-08-25
CA2789244A1 (en) 2011-08-25
WO2011102845A1 (en) 2011-08-25
US20130142792A1 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
JP5558810B2 (ja) Ｒａｇｅ融合タンパク質、製剤及びその使用方法
EP1781700B1 (en) Rage fusion proteins and methods of use
US20080199467A1 (en) Immunoglobulin fusion proteins and methods of making
US20090004190A1 (en) Rage Fusion Proteins And Methods Of Use
US20090060925A1 (en) Rage Fusion Proteins and Methods of Use
US20130142792A1 (en) RAGE Fusion Protein Compositions And Methods Of Use
NL2001554C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001555C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001556C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001558C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001553C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001557C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
NL2001551C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.
HK1133042A (en) Rage fusion proteins, formulations, and methods of use thereof
NL2001552C2 (nl) Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131016

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150706

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151215